Analysis of cardiac magnetic resonance imaging traits in 29,000 individuals reveals shared genetic basis with dilated cardiomyopathy

Brief Title

Large-scale GWAS for cardiac structure and function

Authors

James P. Pirruccello, MD^{a,b,c}; Alexander Bick, MD, PhD^{a,b,c}; Minxian Wang, PhD^c; Mark Chaffin, MS^c; Steven A. Lubitz, MD^{a,b,c,d}; Patrick T. Ellinor, MD, PhD^{a,c,d}; Amit V Khera, MD^{a,b,c}; Sekar Kathiresan, MD^{a,b,c,d,e}; Krishna G. Aragam, MD, MS^{*,a,b,c}

Affiliations

From ^athe Massachusetts General Hospital Division of Cardiology, Boston, Massachusetts; ^bthe Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts; ^cthe Program in Medical and Population Genetics at the Broad Institute, Cambridge, Massachusetts; ^dHarvard Medical School, Boston, Massachusetts; and ^eVerve Therapeutics, Cambridge, Massachusetts.

Word Count

4,790

Funding

This work was funded by the National Institutes of Health RO1 HL127564 (to S.K.), the National Human Genome Research Institute of the US National Institutes of Health under award number 5UM1HG008895 (to S.K.), and the Ofer and Shelly Nemirovsky Research Scholar Award from Massachusetts General Hospital (to S.K.). K.G.A. is supported by the American Heart Association Institute for Precision Cardiovascular Medicine (17IFUNP33840012). J.P.P. is supported by the John S. LaDue Memorial Fellowship for Cardiovascular Research. S.A.L. is supported by NIH grant 1R01HL139731 and American Heart Association 18SFRN34250007. P.T.E. is supported by the Fondation Leducq (14CVD01), the NIH (1R01HL092577, R01HL128914, K24HL105780) and the American Heart Association (18SFRN34110082).

Disclosures

S.K. is an employee of Verve Therapeutics, and holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; he has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, and Medscape; he reports patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). S.A.L. receives sponsored research support

from Bristol Myers Squibb / Pfizer, Bayer AG, and Boehringer Ingelheim, and has consulted for Bristol Myers Squibb / Pfizer and Bayer AG. P.T.E. is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases, and has served on advisory boards or consulted for Bayer AG, Quest Diagnostics, and Novartis. The remaining authors have nothing to disclose.

Address for Correspondence

Krishna G. Aragam, MD, MS, Cardiovascular Genetics Program & Center for Genomic Medicine, Massachusetts General Hospital, 55 Fruit Street GRB 852, Boston, MA 02114, karagam@partners.org

Author Contributions

J.P.P., S.K., and K.G.A. conceived of the study. J.P.P., M.W., and M.C. performed the computational analysis. A.B., S.A.L., P.E., and A.V.K. contributed to the analysis plan and provided critical revisions. J.P.P. and K.G.A. wrote the manuscript.

Acknowledgements

This work was conducted using the UK Biobank under application 7089.

Abstract

Dilated cardiomyopathy (DCM) is an important cause of heart failure and the leading indication for heart transplantation. Many rare genetic variants have been associated with DCM, but common variant studies of the disease have yielded few associated loci. As structural changes in the heart are a defining feature of DCM, we conducted a genome-wide association study (GWAS) of cardiac magnetic resonance imaging (MRI)-derived left ventricular measurements in 29,041 UK Biobank participants. 26 novel loci were associated with cardiac structure and function. These loci were found near 17 genes previously shown to cause Mendelian cardiomyopathies. A polygenic score of left ventricular end systolic volume was associated with incident DCM in previously disease-free individuals (hazard ratio = 1.54 per one standard deviation increase in the polygenic score, $P = 2.1 \times 10^{-16}$). Even among carriers of truncating mutations in *TTN*, the polygenic score influenced the size and function of the heart. These results further implicate common genetic polymorphisms in DCM pathogenesis.

Introduction

Affecting one in every 250 people, dilated cardiomyopathy (DCM) is a disease of cardiac muscle that leads to heart failure, and is the most common indication for cardiac transplantation¹. Rare variants in dozens of genes have been associated with DCM². The most commonly identified mutations are truncating variants in *TTN* (*TTN*tv), which are found in 15-20% of DCM cases. However, rare variants in cardiomyopathy-related genes yield a genetic diagnosis for DCM in approximately 40% of cases². Furthermore,

sequencing efforts in large populations are now identifying an increasing number of individuals who harbor rare DCM-associated variants, but do not manifest clinical disease^{3–6}.

A putative explanation for the limited diagnostic yield and incomplete penetrance of rare DCM-associated variants is that common genetic variation plays a role in the genetic architecture of DCM. To gain insight into the relationship between common genetic variants and DCM, one exome-wide association study⁷ and two genome-wide association studies (GWAS)^{8,9} have been conducted. Nine loci with variants that distinguished cases from controls at a genome-wide level of significance were identified, and four of these loci contain genes that also harbor rare DCM-causing mutations (*TTN*, *ALPK3*, *BAG3*, *FLNC*). These studies have successfully linked common variants to DCM, though their yield has been limited by modest sample sizes, as each study had fewer than 5,000 cases.

As structural changes to the left ventricle are a defining—and frequently incipient—feature of DCM, genetic analyses of cardiac imaging traits present another plausible method for genetic discovery^{10,11}. Several GWAS of cardiac imaging phenotypes have probed the link between common genetic variants and changes in cardiac structure and function. For example, a large-scale genetic study of over 46,000 participants with transthoracic echocardiography (TTE)-derived phenotypes identified five genome-wide significant loci. Notably, one locus, near *PLN*, is associated with Mendelian cardiomyopathies^{12,13}.

A subsequent study using TTE in 19,000 participants from BioBank Japan yielded five additional novel loci, including a locus near *VCL* that is also associated with cardiomyopathies^{14–16}. Finally, a study of 6,765 African American participants with cardiac imaging, including 1,210 with cardiac magnetic resonance imaging (MRI) from the Multi-ethnic Study of Atherosclerosis (MESA), yielded four suggestive loci that have not been subsequently confirmed¹⁷. Together, these studies highlight the potential value of population-based cardiac imaging to gain clinical and biological insights into myocardial diseases. Whether common genetic variants related to the heart's structure and function can identify as-yet unaffected individuals at risk for DCM remains uncertain.

In this study, we sought to discover common genetic variants associated with cardiac structure and function, and to assess whether those common variants influenced the propensity of unrelated individuals to develop DCM. We performed these analyses in the UK Biobank, a population-based cohort of over 500,000 participants^{18,19}. Within this cohort, a large imaging sub-study is underway, with plans to perform cardiac MRI in 100,000 participants^{20,21}. The phenotypic characteristics of the first 5,000 participants have been described in detail^{22,23}. Here, we analyzed automated measurements from the first 29,041 participants—the largest available cardiac MRI dataset—in order to study the relationship between common genetic variants, cardiac phenotypes, and risk for the development of DCM.

Results

Phenotype refinement and cardiac MRI results

We identified 29,041 UK Biobank participants with cardiac MRI readings who had no diagnosis of congestive heart failure (CHF), coronary artery disease (CAD), or DCM at the time of enrollment (**Supplemental Table 1** and **Supplemental Figure 1**). For these individuals, seven cardiac MRI-derived phenotypes were available: left ventricular end diastolic volume (LVEDV), left ventricular end systolic volume (LVESV), stroke volume (SV), the body-surface-area indexed versions of each of these traits (LVEDVi, LVESVi, and SVi), and left ventricular ejection fraction (LVEF). These individuals were majority female (52.6%) and had a mean age 63.6 years at the time of MRI. For women, the mean LVEDV, LVESV, and SV were 122.6mL, 41.1mL, and 81.5mL, respectively; for men, they were 152.8mL, 57.4mL, and 95.4mL (**Supplemental Table 2**). The LVEF averaged 0.67 for women and 0.63 for men (**Supplemental Figure 2**).

Cardiac structure and function are heritable

We asked whether the cardiac MRI phenotypes were influenced by participants' genetic backgrounds. SNP-based heritability—the proportion of variance explained by all SNPs on a genotyping array—was 45% for LVEDV, 43% for LVESV, and 31% for LVEF. Genetic correlations between these cardiac MRI phenotypes were similar in magnitude to their epidemiologic correlations (**Supplemental Figures 3 and 4**).

37 genetic loci are associated with left ventricular size and function

Having established a genetic basis for variability in cardiac structure and function, we then performed a GWAS to identify common genetic variants associated with the seven cardiac MRI phenotypes. 37 distinct loci in the human genome were associated with one or more cardiac MRI phenotypes at genome-wide significance ($P < 5 \times 10^{-8}$; **Table 1**). LD score regression revealed modest test statistic inflation, consistent with polygenicity rather than population stratification (**Supplemental Table 3**).

Of the 37 genome-wide significant loci, 26 were novel and had not been described in prior common variant analyses of dilated cardiomyopathy or cardiac imaging phenotypes. In total, 14 loci associated with LVEDV, eight with LVEDVi, 24 with LVESV, 19 with LVESVi, 16 with LVEF, three with SV, and six with SVi (**Figure 1**).

Among our genome-wide significant loci, we found five of the 10 loci previously discovered through genetic analyses of echocardiographic measurements, including SNPs near *PLN*, *SH2B3/ATXN2*, *MTSS1*, *SMARCB1*, and *CDKN1A*^{13,14}. In addition, we recovered six of the nine loci previously identified at exome- or genome-wide significance in common variant studies of heart failure or cardiomyopathy, including SNPs near *ALPK3*, *BAG3*, *CLCNKA/HSPB7*, *FHOD3*, *FLNC*, and *TTN*⁷⁻⁹.

GWAS loci are enriched for genes expressed in cardiac and skeletal muscle

In order to understand the tissue specificity of the discovered loci, we applied MAGMA, which revealed an enrichment of variants clustered near genes expressed in cardiac and skeletal muscle tissue types, with results for LVESV, LVESVi, and LVEF achieving a Bonferroni-corrected significance threshold (**Supplemental Figure 5**).

GWAS loci are enriched for Mendelian cardiomyopathy-linked genes

We then asked whether the 37 GWAS loci were in proximity to more Mendelian cardiomyopathy genes (from the panel of 129 genes in **Supplemental Table 4**) than expected based on chance. Out of 100,000 simulations, none was linked to more than 14 Mendelian genes (**Supplemental Figure 6a**); in contrast, our loci are near 17 Mendelian genes from the gene panel (**Supplemental Table 5**), were significantly enriched for Mendelian cardiomyopathy genes ($P < 1 \times 10^{-5}$). For comparison, the prior cardiomyopathy GWAS studies identified loci near eight Mendelian cardiomyopathy genes, of which seven are also identified in this study (**Supplemental Figure 6b**).

PheWAS links cardiac MRI polygenic scores with dilated cardiomyopathy in a cross-sectional analysis

We also produced polygenic scores for each trait, weighting the genetic dosage by the effect size of the lead SNPs from each GWAS from **Table 1**. We performed a

cross-sectional phenome-wide association study (PheWAS) in over 450,000 UK Biobank participants to assess the relationship between each of the seven polygenic scores and disease phenotypes. We first performed a PheWAS using a broad set of PheCodes²⁴, 1,598 of which were present in 20 or more participants. As anticipated, this analysis showed an enrichment for cardiac diseases. We then performed a PheWAS for 96 diseases using curated definitions (as defined in **Supplemental Table 1**). Among our curated disease traits, DCM emerged as the disease most strongly associated with the polygenic scores for LVEF, LVEDV, LVESV, LVESVi. The LVESVi polygenic score had the single strongest relationship with DCM (OR 1.47 per standard deviation [SD] increase in LVESVi polygenic score; $P = 1.3 \times 10^{-23}$; **Figure 2**). The strongest relationships between each of the 7 polygenic scores and the disease phenotypes are shown in **Supplemental Table 6** and **Supplemental Figure 7**.

A polygenic score for LVESVi is associated with incident dilated cardiomyopathy

Having established a strong relationship between the common variant-derived polygenic scores identified in our study and DCM in the cross-sectional PheWAS, we then asked whether these polygenic scores also predicted incident disease. The association between polygenic scores and incident DCM (388 cases) was assessed in the remaining 358,556 individuals in the UK Biobank without cardiac MRI data, after excluding those with cardiac disease at baseline, and those with third-degree or closer relatedness to another participant (**Supplemental Table 7**). The polygenic scores for

LVEDV, LVESV, LVEF, LVEDVi, and LVESVi were significantly associated with incident DCM after adjusting for age, sex, genotyping batch, and the first five principal components of ancestry in separate Cox proportional hazards models for each phenotype.

The 19-SNP LVESVi polygenic score had the strongest relationship with incident DCM (hazard ratio [HR] = 1.54 per SD increase in the score, $P = 2.1 \times 10^{-16}$). The direction was consistent with clinical expectations: a greater genetically mediated LVESVi corresponded with a higher risk of DCM, while a lower polygenic risk corresponded to a lower risk of DCM. The cumulative incidence of DCM among those in the top 10%, bottom 10%, and middle 80% for the polygenic score are plotted in **Figure 3**. For each trait, the relationship between its polygenic score and incident DCM is available in **Supplemental Table 8**.

A polygenic score for LVESVi influences left ventricular structure and function in individuals harboring rare truncating variants in *TTN*

Finally, to understand whether common genetic variants might contribute to the incomplete penetrance and variable expressivity of DCM-associated rare variants, we asked whether the 19-SNP LVESVi polygenic score affected the structure and function of the heart among carriers of high-impact truncating mutations in *TTN* (TTNtv). Rare TTNtv were chosen for analysis because of their established roles in cardiomyopathy and preclinical cardiac dysfunction, as well as their relatively high population frequency

(approximately 0.5%). Among the 11,878 participants who had undergone both cardiac MRI and exome sequencing, we identified 53 carriers of TTNtv in exons spliced into over 90% of transcripts in the heart (**Supplemental Table 9**). We found that the polygenic background of TTNtv carriers influenced both left ventricular volume and function: the LVEDV of TTNtv carriers was influenced by the LVESVi polygenic score (12.0mL increase in LVEDV per SD increase in the score, $P = 0.011$), as was LVESV (9.1mL increase in LVESV per SD, $P = 0.008$). The LVEF was also reduced by 2.8% per SD of the LVESVi score ($P = 0.017$).

Discussion

In this study, we identified 26 novel, common genetic variants associated with the structure and function of the heart in individuals without overt cardiovascular disease; linked our identified common variants to DCM through multiple lines of evidence; established that a polygenic score derived from common genetic variants predicts incident DCM; and demonstrated that a common genetic background affects cardiac traits even among carriers of cardiomyopathy-related rare variants.

These results permit several conclusions. First, common genetic variants associated with left ventricular structure and function contribute to DCM risk. In an incident disease analysis, our best performing polygenic score—created from 19 SNPs from our LVESVi GWAS—robustly predicted DCM (HR 1.54 per standard deviation increase, $P = 2 \times 10^{-16}$). This is the first instrument derived from common genetic variants that has been

demonstrated to associate with incident DCM. That the common genetic variants contributing to the LVESVi polygenic score were identified after excluding individuals with any known cardiac disease—yet still predicted cardiomyopathy—suggests an intrinsic connection between the common genetic determinants of normal cardiac traits and risk for DCM. These results raise the possibility that, in some individuals, DCM may reflect the extremes of normal phenotypic variation, driven by a high burden of common variants. This may, in part, explain the incomplete yield of genetic testing for rare variants in DCM. Future studies are required to determine the relative contributions of—and potential interplay between—common variants, rare variants, and environmental factors in the pathogenesis of DCM.

Second, genetic analyses of quantitative cardiac imaging traits may improve our understanding of the common genetic basis of cardiomyopathies. In our prior genetic analysis of the UK Biobank, we refined a heterogeneous heart failure phenotype to a specific, nonischemic cardiomyopathy subset, enabling detection of two DCM risk loci (near *BAG3* and *CLCNKA*) that associated with subclinical changes in LV structure and function²⁵. Similarly, seminal GWAS studies of dilated cardiomyopathy yielded 9 risk loci, but were limited by the recruitment of cardiomyopathy cases^{7–9}. Here, by pursuing a genetic analysis of cardiac MRI-derived traits in individuals without clinical disease, we recovered the majority of previously reported cardiomyopathy risk loci, and discovered loci near an additional 10 Mendelian cardiomyopathy genes (**Supplemental Figure 6**). Additionally, our PheWAS confirmed in an unbiased fashion that the genetic loci from

these phenotypes were strongly associated with cardiomyopathies. Further analyses of MRI-derived cardiac traits may permit efficient study of the genetic determinants of cardiac structure and function in both health and disease, complementing the growing case-control genetic studies of cardiomyopathies.

Third, our results provide new insights into the role that common genetic variants play in determining the structure and function of the heart, even in the context of rare, high-impact mutations in cardiomyopathy-related genes. In a prior analysis of *TTN*tv, *TTN*tv carrier status associated with changes in LVEDV (+11.8mL), LVESV (+7.7mL), and LVEF (-2.8%) in individuals without clinical DCM⁶. In the present study, among carriers of cardiac-relevant *TTN*tv (those spliced into at least 90% of transcripts in the heart), a 1-SD increase in the LVESVi polygenic score associated with comparable changes in LVEDV (+12.0mL), LVESV (+9.1mL), and LVEF (-2.8%). These findings emphasize the potential scope and impact of common genetic variants on cardiac structure and function, and suggest that the penetrance of high-impact rare variants may be influenced by carriers' polygenic backgrounds: for example, individuals with a *TTN* truncation but a favorable genetic background may be less likely to develop a reduced LVEF. Future studies will be required to understand if these individuals might be protected from cardiomyopathy.

Finally, our results highlight the importance of costameres to variation in cardiac traits. Costameres are cytoskeletal assemblies that connect the sarcomere—the basic

structural unit of muscle—to the cell membrane and the extracellular matrix.

Costameres include protein complexes such as the dystrophin glycoprotein complex (DGC) and the vinculin-talin-integrin system²⁶. Both the DGC and the vinculin-talin-integrin system play roles in mechanical anchoring, while the vinculin-talin-integrin system also plays a role in mechanosensation and signal transduction²⁷. Notably, three lead SNPs' nearest genes (*FLNC*, *SSPN*, and *PXN*) play key roles in costamere biology. γ -filamin (produced by *FLNC*) links the membrane-bound DGC with sarcomeric actin filaments²⁸. *PXN* produces a protein (paxillin) that binds to vinculin and integrin to form part of the vinculin-talin-integrin system²⁹. Finally, sarcospan, the protein product of *SSPN*, is a part of the DGC and is required for DGC-integrin interactions^{30,31}. The emergence of these loci from our unbiased genetic analysis of cardiac MRI phenotypes underscores the importance of the costamere within the cardiomyocyte, and suggests that compromise of its protein assemblies may contribute to the development of cardiomyopathies.

Study limitations

There are several limitations to our findings. First, our analyses were limited to older individuals of predominantly European ancestry, which may limit their applicability to younger individuals and those of other ancestries. Second, the cardiac measurements are derived from automated readings. Although we excluded gross anatomical mistracings in images at the tails of the distribution, these exclusions would not correct for algorithmic biases in the automated reading software. Third, because the UK Biobank relied on hospitalization or death to assign disease status, unrecognized

disease at baseline may have occurred for individuals without any pre-enrollment hospitalizations.

Conclusions

In conclusion, we report 26 novel, common genetic loci associated with left ventricular structure and function as measured by cardiac MRI, and reveal a robust link to dilated cardiomyopathy.

Methods

Study participants

The UK Biobank is a richly phenotyped, prospective, population-based cohort ¹⁹. In total, we analyzed 487,283 participants with genetic data who had not withdrawn consent as of October 2018. Analysis of the UK Biobank data was approved by the Partners Health Care institutional review board (protocol 2013P001840).

Phenotype refinement

Disease phenotypes in the UK Biobank were defined using a combination of self-reported data (confirmed by a healthcare professional), hospital admission data, and death registry data. We defined nonischemic dilated cardiomyopathy (DCM) as a billing code diagnosis of dilated cardiomyopathy (ICD-10 code I42.0) in the absence of coronary artery disease. Algorithms for identifying individuals with DCM, heart failure from any cause, and coronary artery disease in the UK Biobank are available in

Supplemental Table 1, as previously described ²⁵.

Cardiac MRI measurements

Cardiac magnetic resonance imaging was performed with 1.5 Tesla scanners (MAGNETOM Aera, Syngo Platform vD13A, Siemens Healthcare) with electrocardiographic gating for cardiac synchronization ²¹. Cardiac assessment was performed from the combination of several cine series using balanced steady-state free

precession acquisitions, with post-processing by cvi42 Version 5.1.1²². Because of known bias in the vD13A automated measurements, a bias correction was applied for left ventricular end diastolic volume (LVEDV) and left ventricular end systolic volume (LVESV) measurements, using linear corrections derived from a UK cohort undergoing imaging on the same MRI platform³².

Values for left ventricular ejection fraction (LVEF) and stroke volume (SV) were calculated from the LVEDV and LVESV: $LVEF = \frac{(LVEDV - LVESV)}{LVEDV}$ and $SV = LVEDV - LVESV$. Body surface area (BSA)-indexed values were produced for left ventricular end diastolic volume (LVEDVi), left ventricular systolic volume (LVESVi), and stroke volume (SVi) by, respectively, dividing the values for LVEDV, LVESV, and SV by the individual's Mosteller BSA: $\sqrt{\frac{(height\ in\ cm) * (weight\ in\ kg)}{3600}}$ ³³.

Cardiac MRI sample selection and quality control

At the time of analysis in June 2019, we identified 31,931 individuals with cardiac MRI data. To account for errors in the automated volume measurement system, two cardiologists (JPP and KGA) manually reviewed images for samples having LVEDV or LVESV beyond 1.5 interquartile range below the first quartile or above the third quartile³⁴. 610 samples identified as having gross anatomic mistracings were rejected. 1,308 samples that did not pass genotyping quality control, detailed below, were excluded. Data from 870 individuals with incident or prevalent heart failure, dilated cardiomyopathy, hypertrophic cardiomyopathy, or coronary artery disease were

excluded. Finally, we removed 102 samples with LVEDV or LVESV beyond 4 standard deviations above or below the mean. After these exclusions, 29,041 samples remained for analysis (flow diagram displayed in **Supplemental Figure 1**).

Genotyping and quality control

UK Biobank samples were genotyped on either the UK BiLEVE or UK Biobank Axiom arrays, then imputed into the Haplotype Reference Consortium panel and the UK10K + 1000 Genomes panel¹⁸.

We performed genotyping quality control by excluding genotyped variants with call rate < 0.95, imputed variants with INFO score < 0.3, imputed or hard-called variants with minor allele frequency less than 0.001 in the overall UK Biobank population, or imputed or hard-called variants with an effective minor allele count of less than 100 in the subset of individuals with cardiac MRI data. To calculate the effective minor allele count, the minor allele frequency was multiplied by the number of alleles in the analysis and by the imputation INFO score provided by the UK Biobank¹⁸. After exclusions, 13,660,711 autosomal variants were analyzed. Variant positions were keyed to GRCh37/hg19.

We performed sample quality control by excluding samples that had no imputed genetic data; a genotyping call rate < 0.98; a mismatch between submitted and inferred sex; sex chromosome aneuploidy (neither XX nor XY); exclusion from kinship inference;

excessive third-degree relatives; or that were outliers in heterozygosity or genotype missingness rates as defined centrally by the UK Biobank¹⁸.

Heritability analysis

Heritability attributable to single nucleotide polymorphisms (SNPs) at the 784,256 directly genotyped sites that passed quality control was computed with the `--reml` option from BOLT-LMM (version 2.3.2)³⁵. Cross-trait genetic correlations between LVESV, LVEDV, and LVEF were computed with the same command.

Genome-wide association study

We performed genome-wide association studies (GWAS) using linear mixed models with BOLT-LMM (version 2.3.2) to account for ancestral heterogeneity, cryptic population structure, and sample relatedness^{35,36}.

Because the cardiac MRI data released by the UK Biobank comprised the majority of cardiac MRIs ever released in a research setting, we implemented a within-cohort replication strategy. First, we used the initial 24,216 samples with MRI data released by the UK Biobank through December 2018 to conduct a genome-wide association study (GWAS) for each of 7 cardiac MRI phenotypes: LVEDV, LVESV, LVEF, SV, LVEDVi, LVESVi, and SVi. Each GWAS was adjusted for the first five principal components of ancestry, sex, year of birth, age at the time of MRI, and the MRI scanner's unique identifier to account for batch effects. We repeated each GWAS in the replication set of 4,825 samples that were made available in March 2019. With this replication strategy,

we took SNPs forward for a final joint analysis if they (1) achieved $P < 1 \times 10^{-4}$ in the initial analysis and (2) had the same direction of effect in the replication analysis.

We then conducted a joint GWAS in all 29,041 samples for any SNP that achieved nominal replication. Variants with association $P < 5 \times 10^{-8}$ in the joint analysis were considered to be genome-wide significant. The most strongly associated SNP at each locus is referred to as the “lead SNP.” The gene in closest physical proximity to each lead SNP was designated as the gene label associated with each locus; however, if a Mendelian cardiac disease-associated gene was located within 250kb of the lead SNP, then the locus was named after the nearest Mendelian gene.

LD score regression was performed with ldsc (version 1.0.0) to partition the genomic control factor lambda into polygenic and inflation components³⁷. Allelic heterogeneity was assessed by clumping at each genome-wide significant locus to identify additional variants having trait association $P < 5 \times 10^{-8}$ and $r^2 < 0.2$ with other independent genome-wide significant variants within 1 megabase of the top variant at each locus using FUMA³⁸.

Tissue enrichment

From the associated SNPs for each genotype, we evaluated the associations of 10,678 gene sets from MSigDB v6.2 and gene expression sets from GTEx using MAGMA^{39–41}. Tissue enrichment tests were executed on the FUMA platform v1.3.4b³⁸. A

Bonferroni-corrected threshold of $\frac{0.05}{53 \text{ tissue types}} = 9.4 \times 10^{-4}$ was considered statistically significant enrichment of a tissue type.

Mendelian cardiomyopathy gene set enrichment

To create an unbiased list of genes associated with Mendelian cardiomyopathies and congenital heart abnormalities, we assembled genes from three commercially available cardiomyopathy gene panels (GeneDx Cardiomyopathy Panel, 207 Perry Parkway, Gaithersburg, MD, USA; Invitae Cardiomyopathy Comprehensive Panel, 1400 16th Street, San Francisco, CA, USA; Partners Laboratory for Molecular Medicine Pan Cardiomyopathy Panel, 77 Avenue Louis Pasteur Suite 250, Boston, MA, USA).

Together, these panels contained 129 genes (**Supplemental Table 4**), all of which mapped to transcripts with HG19 coordinates. SNPsnap was used to generate 100,000 sets of SNPs that match the lead SNPs from the GWAS based on minor allele frequency, number of SNPs in linkage disequilibrium, distance to the nearest gene, and gene density at the locus⁴². A SNP was considered to be near a Mendelian locus if it was within 1 megabase upstream or downstream of any gene on the panel. Significance was assessed by permutation testing across the 100,000 SNP sets to determine the neutral expectation for the number of overlapping genes in loci with characteristics similar to ours.

Polygenic score creation

For each individual, we calculated a polygenic score by taking the beta for each lead SNP multiplied by the genetic dosage of the effect allele, and summing this value for each lead SNP from **Table 1** for that trait. We repeated this procedure for each of the 7 traits, producing 7 polygenic scores.

Phenome-wide association study

We performed a phenome-wide association study (PheWAS) in the 456,237 individuals with genetic data who had not undergone cardiac MRI. We tested polygenic scores produced for each of the 7 cardiac traits for association with 96 manually curated disease phenotypes and 1,598 ICD-10 mapped PheCodes which were present in 20 or more individuals in the UK Biobank²⁴. Associations between the polygenic score and each phenotype were modeled with logistic regression, accounting for age at enrollment, sex, the genotyping array, and the first 5 principal components of ancestry as covariates.

Testing polygenic score association with incident dilated cardiomyopathy

We assessed the relationship between the polygenic scores and DCM in the 358,556 participants who had not undergone cardiac MRI, were free from CHF, DCM, and CAD at baseline, and who were not identified by the UK Biobank as having third-degree or closer relatedness to another participant¹⁸. This sample included 388 individuals with incident DCM. We tested each score separately for association with incident DCM using

a Cox proportional hazards model. This model was adjusted for sex, genotyping array, the first five principal components of ancestry, and the cubic basis spline of age at enrollment. Cox modeling was performed with the *survival* package in R 3.4.4 (R Foundation for Statistical Computing, Vienna, Austria). We defined statistical significance as a two-tailed $P < (0.05 / 7 \text{ phenotypes}) = 0.007$.

For plotting, the samples were divided into deciles by LVESVi polygenic score. DCM incidence over time was plotted for the individuals in the lowest 10% of the LVESVi polygenic score, those in the highest 10%, and those in the remaining 80% using the *survminer* package in R.

Testing the polygenic score within TTNtv carriers

As described by Van Hout, *et al*, samples from the UK Biobank were prioritized for exome sequencing based on the presence of MRI data and linked records⁴. Exomes were generated by the Regeneron Genetics Center, and reprocessed by the UK Biobank according to Functional Equivalent standards⁴³. In total, 49,997 exomes were available. Variants in *TTN* were annotated with the Ensembl Variant Effect Predictor version 95 with the `--pick-allele` flag⁴⁴. LOFTEE was used to identify high-confidence loss of function variants in *TTN* (TTNtv): namely, stop-gained, splice-site disrupting, and frameshift variants⁴⁵.

Of the samples with cardiac MRI that passed all of the disease exclusion and quality control measures described above, 11,878 also had exome sequencing. Of these, 53 samples had TTNtv in exons which are spliced into more than 90% of transcripts in the heart (“high-PSI”), which are likely to be relevant to cardiac phenotypes⁵.

We applied the the polygenic score most predictive of DCM (derived from the LVESVi) to the TTNtv carriers, and assessed whether that score was associated with LVESV, LVEDV, and LVEF in those individuals after adjustment for the first five principal components of ancestry, genotyping array, sex, and the cubic basis spline of age at enrollment. To minimize the risk of weak-instrument bias⁴⁶, we re-computed weights for the best performing polygenic score (LVESVi) while excluding the 53 TTNtv carriers from the LVESVi GWAS. The original polygenic score and the recomputed score were similar ($R^2 = 0.9999$ across the 53 samples with TTNtv). We defined statistical significance as a two-tailed $P < (0.05 / 3 \text{ phenotypes}) = 0.017$.

Data Availability

Data is made available from the UK Biobank to researchers from universities and other research institutions with genuine research inquiries following IRB and UK Biobank approval.

References

1. Khush, K. K. *et al.* The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-fifth Adult Heart Transplantation Report—2018; Focus Theme: Multiorgan Transplantation. *J. Heart Lung Transplant.* **37**, 1155–1168 (2018).
2. Hershberger, R. E., Hedges, D. J. & Morales, A. Dilated cardiomyopathy: the complexity of a diverse genetic architecture. *Nat. Rev. Cardiol.* **10**, 531–547 (2013).
3. Haggerty Christopher M. *et al.* Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. *Circulation* **140**, (2019).
4. Hout, C. V. V. *et al.* Whole exome sequencing and characterization of coding variation in 49,960 individuals in the UK Biobank. *bioRxiv* 572347 (2019).
doi:10.1101/572347
5. Roberts, A. M. *et al.* Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease. *Sci. Transl. Med.* **7**, 270ra6 (2015).
6. Schafer, S. *et al.* Titin-truncating variants affect heart function in disease cohorts and the general population. *Nat. Genet.* **49**, 46–53 (2017).
7. Esslinger, U. *et al.* Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. *PLOS ONE* **12**, e0172995 (2017).
8. Meder, B. *et al.* A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. *Eur. Heart J.* **35**, 1069–1077 (2014).

9. Villard, E. *et al.* A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. *Eur. Heart J.* **32**, 1065–1076 (2011).
10. Mahon, N. G. *et al.* Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. *Ann. Intern. Med.* **143**, 108–115 (2005).
11. Pinto, Y. M. *et al.* Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. *Eur. Heart J.* **37**, 1850–1858 (2016).
12. Schmitt, J. P. *et al.* Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. *Science* **299**, 1410–1413 (2003).
13. Wild, P. S. *et al.* Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function. *J. Clin. Invest.* **127**, 1798–1812 (2017).
14. Kanai, M. *et al.* Genetic analysis of quantitative traits in the Japanese population links cell types to complex human diseases. *Nat. Genet.* **50**, 390 (2018).
15. Olson, T. M. *et al.* Metavinculin mutations alter actin interaction in dilated cardiomyopathy. *Circulation* **105**, 431–437 (2002).
16. Vasile, V. C., Ommen, S. R., Edwards, W. D. & Ackerman, M. J. A missense mutation in a ubiquitously expressed protein, vinculin, confers susceptibility to hypertrophic cardiomyopathy. *Biochem. Biophys. Res. Commun.* **345**, 998–1003 (2006).

17. Fox, E. R. *et al.* Genome-Wide Association Study of Cardiac Structure and Systolic Function in African Americans: The Candidate Gene Association Resource (CARE) Study. *Circ. Cardiovasc. Genet.* **6**, 37–46 (2013).
18. Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203 (2018).
19. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
20. Petersen, S. E. *et al.* Imaging in population science: cardiovascular magnetic resonance in 100,000 participants of UK Biobank - rationale, challenges and approaches. *J. Cardiovasc. Magn. Reson.* **15**, 46 (2013).
21. Petersen, S. E. *et al.* UK Biobank's cardiovascular magnetic resonance protocol. *J. Cardiovasc. Magn. Reson.* **18**, (2016).
22. Petersen, S. E. *et al.* Reference ranges for cardiac structure and function using cardiovascular magnetic resonance (CMR) in Caucasians from the UK Biobank population cohort. *J. Cardiovasc. Magn. Reson.* **19**, 18 (2017).
23. Petersen, S. E. *et al.* The impact of cardiovascular risk factors on cardiac structure and function: Insights from the UK Biobank imaging enhancement study. *PLOS ONE* **12**, e0185114 (2017).
24. Wu, P. *et al.* Developing and Evaluating Mappings of ICD-10 and ICD-10-CM Codes to PheCodes. *bioRxiv* 462077 (2019). doi:10.1101/462077
25. Aragam Krishna G *et al.* Phenotypic Refinement of Heart Failure in a National

- Biobank Facilitates Genetic Discovery. *Circulation* **0**, (2018).
26. Jaka, O., Casas-Fraile, L., López de Munain, A. & Sáenz, A. Costamere proteins and their involvement in myopathic processes. *Expert Rev. Mol. Med.* **17**, e12 (2015).
 27. Israeli-Rosenberg Sharon, Manso Ana Maria, Okada Hideshi & Ross Robert S. Integrins and Integrin-Associated Proteins in the Cardiac Myocyte. *Circ. Res.* **114**, 572–586 (2014).
 28. Thompson, T. G. *et al.* Filamin 2 (Fln2). *J. Cell Biol.* **148**, 115–126 (2000).
 29. Kanchanawong, P. *et al.* Nanoscale architecture of integrin-based cell adhesions. *Nature* **468**, 580–584 (2010).
 30. Crosbie, R. H., Heighway, J., Venzke, D. P., Lee, J. C. & Campbell, K. P. Sarcospan, the 25-kDa transmembrane component of the dystrophin-glycoprotein complex. *J. Biol. Chem.* **272**, 31221–31224 (1997).
 31. Parvatiyar Michelle S. *et al.* Sarcospan Regulates Cardiac Isoproterenol Response and Prevents Duchenne Muscular Dystrophy–Associated Cardiomyopathy. *J. Am. Heart Assoc.* **4**, e002481 (2015).
 32. Sanghvi, M. M. *et al.* Automatic left ventricular analysis with Inline VF performs well compared to manual analysis: results from Barts Cardiovascular Registry. *J. Cardiovasc. Magn. Reson.* **18**, P31 (2016).
 33. Mosteller, R. Simplified Calculation of Body-Surface Area. *N. Engl. J. Med.* **317**, 1098–1098 (1987).
 34. Tukey, J. W. *Exploratory data analysis*. (Addison-Wesley Pub. Co., 1977).

35. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in large cohorts. *Nat. Genet.* **47**, 284–290 (2015).
36. Loh, P.-R., Kichaev, G., Gazal, S., Schoech, A. P. & Price, A. L. Mixed-model association for biobank-scale datasets. *Nat. Genet.* **50**, 906–908 (2018).
37. Bulik-Sullivan, B. K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat. Genet.* **47**, 291–295 (2015).
38. Watanabe, K., Taskesen, E., Bochoven, A. van & Posthuma, D. Functional mapping and annotation of genetic associations with FUMA. *Nat. Commun.* **8**, 1826 (2017).
39. Lonsdale, J. *et al.* The Genotype-Tissue Expression (GTEx) project. *Nat. Genet.* **45**, 580–585 (2013).
40. de Leeuw, C. A., Mooij, J. M., Heskes, T. & Posthuma, D. MAGMA: Generalized Gene-Set Analysis of GWAS Data. *PLoS Comput. Biol.* **11**, (2015).
41. Liberzon, A. *et al.* The Molecular Signatures Database Hallmark Gene Set Collection. *Cell Syst.* **1**, 417–425 (2015).
42. Pers, T. H., Timshel, P. & Hirschhorn, J. N. SNPsnap: a Web-based tool for identification and annotation of matched SNPs. *Bioinformatics* **31**, 418–420 (2015).
43. Regier, A. A. *et al.* Functional equivalence of genome sequencing analysis pipelines enables harmonized variant calling across human genetics projects. *Nat. Commun.* **9**, 4038 (2018).
44. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).
45. Karczewski, K. J. *et al.* Variation across 141,456 human exomes and genomes

reveals the spectrum of loss-of-function intolerance across human protein-coding genes. *bioRxiv* 531210 (2019). doi:10.1101/531210

46. Haycock, P. C. *et al.* Best (but oft-forgotten) practices: the design, analysis, and interpretation of Mendelian randomization studies. *Am. J. Clin. Nutr.* **103**, 965–978 (2016).

Table 1: Genome-wide significant loci from genetic association analyses of cardiac MRI phenotypes

Locus ID	dbSNP	Chr	Position (hg19)	Effect Allele	Other Allele	Effect Allele Freq	INFO	Beta	SE	P-value	Locus Name
LVEDV											
1	rs28579893	1	16347534	A	G	0.33	1.00	-1.06	0.191	2.40E-08	CLCNKA
2	rs4241246	2	71676366	C	A	0.43	0.99	1.04	0.184	1.10E-08	DYSF
3	rs2562845	2	179514433	T	C	0.80	1.00	1.71	0.226	6.50E-14	TTN
4		3	14291003	CTTTT	C	0.66	0.98	1.13	0.192	4.20E-09	TMEM43
5		3	99522473	TA	T	0.32	0.99	-1.09	0.194	2.40E-08	COL8A1
6	rs1499813	3	171760427	T	C	0.59	1.00	0.99	0.184	4.20E-08	FNDC3B
7	rs11153730	6	118667522	T	C	0.51	1.00	-1.16	0.181	2.20E-10	PLN
8		8	125858538	GA	G	0.69	0.98	1.20	0.197	1.20E-09	MTSS1
9	rs72840788	10	121415685	G	A	0.78	0.98	1.67	0.222	4.80E-14	BAG3
10	rs3184504	12	111884608	T	C	0.47	1.00	-1.22	0.181	1.10E-11	SH2B3
11		15	85348961	TTTTG	T	0.75	0.97	-1.16	0.211	3.00E-08	ALPK3
12	rs71385734	16	2160503	T	G	0.83	0.99	1.52	0.241	3.40E-10	PKD1
13	rs7502466	17	1372970	G	A	0.89	0.98	1.72	0.292	4.00E-09	MYO1C
14	rs12460541	19	46312077	G	A	0.65	1.00	-1.13	0.189	2.30E-09	RSPH6A
LVESV											
15	rs114300540	1	6248182	C	T	0.88	0.90	-0.98	0.171	4.80E-09	RPL22
1	rs945425	1	16348412	T	C	0.32	1.00	-1.06	0.114	6.30E-21	CLCNKA
16	rs111323943	2	45610917	C	CT	0.96	0.90	-1.46	0.270	4.00E-08	SRBD1
2	rs4852257	2	71678520	T	G	0.42	0.99	0.59	0.109	2.80E-08	DYSF
3	rs2255167	2	179558282	T	A	0.81	1.00	1.30	0.136	2.30E-21	TTN
17	rs1394785	2	213210974	G	C	0.29	0.99	0.65	0.118	4.10E-08	ERBB4
4	rs55691578	3	14277060	A	C	0.66	0.98	1.00	0.114	3.00E-18	TMEM43
18		3	52890521	AC	A	0.15	0.99	0.81	0.150	1.30E-08	TNNC1
6	rs1499813	3	171760427	T	C	0.59	1.00	0.63	0.109	2.70E-09	FNDC3B
19	rs34373805	7	128486363	C	T	0.84	1.00	0.81	0.147	1.30E-08	FLNC
8		8	125858538	GA	G	0.69	0.98	0.79	0.117	1.70E-11	MTSS1

20	rs1962104	8	141635329	T	C	0.45	0.98	-0.62	0.109	1.90E-08	AGO2
9	rs72840788	10	121415685	G	A	0.78	0.98	1.52	0.132	7.10E-31	BAG3
21	rs113819537	12	26348429	C	G	0.75	0.99	-0.71	0.124	7.50E-09	SSPN
22	rs116904997	12	120668534	G	A	0.98	0.99	-2.39	0.365	8.20E-11	PXN
23	rs111418232	14	89835905	A	T	0.55	0.87	-0.63	0.116	3.70E-08	FOXN3
11		15	85348961	TTTTG	T	0.75	0.97	-0.83	0.126	2.70E-11	ALPK3
24	rs5029142	16	988070	T	A	0.62	0.99	0.63	0.112	1.10E-08	LMF1
12	rs71385734	16	2160503	T	G	0.83	0.99	0.88	0.144	1.20E-09	PKD1
25	rs117837409	16	4631802	A	G	0.95	0.92	-1.57	0.264	3.30E-09	C16orf96
13	rs7502466	17	1372970	G	A	0.89	0.98	1.07	0.174	1.20E-09	MYO1C
26	rs10445344	17	53367788	T	A	0.73	0.98	0.68	0.122	1.10E-08	HLF
14	rs10421891	19	46315809	A	G	0.64	1.00	-0.75	0.112	7.40E-12	RSPH6A
27	rs2267038	22	24169196	G	C	0.19	1.00	-0.93	0.137	4.70E-12	SMARCB1
LVEF											
28	rs2503715	1	2144107	A	G	0.13	0.91	-0.00358	0.00067	4.10E-08	C1orf86
1	rs9442216	1	16353400	T	C	0.33	1.00	0.00428	0.00045	1.10E-21	CLCNKA
29	rs10925197	1	236842077	C	G	0.46	0.99	0.00237	0.00043	2.50E-08	ACTN2
3	rs2255167	2	179558282	T	A	0.81	1.00	-0.00423	0.00054	1.80E-15	TTN
4	rs73028853	3	14273117	C	T	0.66	0.99	-0.00382	0.00045	3.50E-17	TMEM43
30	rs62253176	3	69906231	T	G	0.81	0.99	-0.00343	0.00055	8.70E-10	MITF
31	rs4835730	5	138763807	T	C	0.33	1.00	0.00250	0.00046	4.10E-08	DNAJC18
32	rs3176326	6	36647289	G	A	0.80	0.99	-0.00381	0.00054	1.80E-12	CDKN1A
19	rs34373805	7	128486363	C	T	0.84	1.00	-0.00355	0.00059	8.70E-10	FLNC
9	rs72840788	10	121415685	G	A	0.78	0.98	-0.00568	0.00053	5.60E-28	BAG3
33	rs58460019	10	129773144	A	ATCAT ACCT	0.75	0.90	0.00285	0.00052	2.20E-08	PTPRE
11	rs8023658	15	85323220	G	T	0.51	0.96	-0.00275	0.00044	4.40E-10	ALPK3
24	rs5015439	16	987358	T	C	0.62	1.00	-0.00242	0.00044	1.80E-08	LMF1
26	rs3794752	17	53382829	T	C	0.72	0.98	-0.00286	0.00048	6.30E-10	HLF
34	rs2047273	18	34184859	T	C	0.68	0.96	-0.00256	0.00047	3.10E-08	FHOD3
27	rs2070458	22	24159307	A	T	0.20	1.00	0.00361	0.00054	1.40E-11	SMARCB1

SV											
3	rs7573293	2	179753245	C	T	0.28	0.99	-0.699	0.124	1.60E-08	TTN
7	rs3951016	6	118559658	T	A	0.53	0.99	0.692	0.111	5.20E-10	PLN
10	rs11065979	12	112059557	C	T	0.57	1.00	0.714	0.112	1.60E-10	BRAP
LVEDVi											
3	rs2042995	2	179558366	T	C	0.77	1.00	0.808	0.107	5.20E-14	TTN
4	rs2170454	3	14294549	T	C	0.46	0.99	-0.505	0.091	4.10E-08	TMEM43
7	rs72967533	6	118655020	T	C	0.52	0.99	-0.529	0.091	7.90E-09	PLN
8		8	125858538	GA	G	0.69	0.98	0.546	0.098	2.00E-08	MTSS1
9	rs11199043	10	121367249	A	G	0.52	0.96	-0.620	0.092	1.80E-11	BAG3
10	rs653178	12	112007756	C	T	0.47	1.00	-0.549	0.090	1.00E-09	ATXN2
13	rs7502466	17	1372970	G	A	0.89	0.98	0.817	0.146	1.80E-08	MYO1C
14	rs12460541	19	46312077	G	A	0.65	1.00	-0.544	0.095	1.00E-08	RSPH6A
LVESVi											
28	rs2503715	1	2144107	A	G	0.13	0.91	0.447	0.081	2.40E-08	C1orf86
1	rs9442216	1	16353400	T	C	0.33	1.00	-0.471	0.054	5.70E-19	CLCNKA
3	rs2042995	2	179558366	T	C	0.77	1.00	0.574	0.061	4.50E-21	TTN
17	rs4673661	2	213205047	A	G	0.28	1.00	0.322	0.057	7.60E-09	ERBB4
4	rs73028849	3	14272766	G	C	0.66	0.99	0.455	0.054	9.10E-17	TMEM43
6	rs1499813	3	171760427	T	C	0.59	1.00	0.289	0.052	9.40E-09	FNDC3B
32	rs3176326	6	36647289	G	A	0.80	0.99	0.383	0.065	4.30E-09	CDKN1A
19	rs34373805	7	128486363	C	T	0.84	1.00	0.380	0.071	3.40E-08	FLNC
8		8	125858538	GA	G	0.69	0.98	0.342	0.056	6.70E-10	MTSS1
20	rs1962104	8	141635329	T	C	0.45	0.98	-0.316	0.052	2.20E-09	AGO2
9	rs72840788	10	121415685	G	A	0.78	0.98	0.671	0.063	3.70E-26	BAG3
21	rs113819537	12	26348429	C	G	0.75	0.99	-0.324	0.059	3.50E-08	SSPN
22	rs116904997	12	120668534	G	A	0.98	0.99	-1.129	0.175	4.30E-10	PXN
11		15	85348961	TTTTG	T	0.75	0.97	-0.347	0.060	7.40E-09	ALPK3

24	rs5029140	16	987972	C	T	0.62	0.99	0.320	0.053	3.90E-10	LMF1
13	rs7502466	17	1372970	G	A	0.89	0.98	0.475	0.083	1.50E-08	MYO1C
26	rs876719	17	53366566	G	T	0.73	0.97	0.354	0.059	7.10E-10	HLF
14	rs10421891	19	46315809	A	G	0.64	1.00	-0.336	0.054	1.90E-10	RSPH6A
27	rs2070458	22	24159307	A	T	0.20	1.00	-0.460	0.065	5.20E-13	SMARCB1
SVi											
2	rs7573293	2	179753245	C	T	0.28	0.99	-0.365	0.063	1.00E-08	TTN
35		2	232288831	TTTC	T	0.68	0.99	-0.371	0.061	1.50E-09	B3GNT7
36	rs2146324	6	43756863	A	C	0.26	0.98	0.357	0.065	4.30E-08	VEGFA
7	rs3951016	6	118559658	T	A	0.53	0.99	0.318	0.057	2.80E-08	PLN
10	rs11065979	12	112059557	C	T	0.57	1.00	0.321	0.057	2.40E-08	BRAP
37	rs7143356	14	23881083	T	C	0.62	1.00	0.319	0.058	4.10E-08	MYH7

Each distinct genomic locus is labeled with a Locus ID from 1-37. For variants which have been assigned an rsID by dbSNP as of version 151, that rsID is listed in the second column. The effect size and standard error were in the following units for each phenotype: mL for LVEDV, LVESV, and SV; ml/m² for LVEDVi, LVESVi, and SVi; and dimensionless (range 0-1) for LVEF. The locus name is based on the gene nearest to each lead SNP, except when there is a Mendelian cardiomyopathy gene from the combined gene panel in **Supplemental Table 4** within 250kb of the lead SNP.

Figures

Figure 1: Manhattan plots of genome-wide association discovery analyses of cardiac MRI phenotypes in the UK Biobank

For each cardiac MRI phenotype, the $-\log_{10}(P \text{ value})$ is graphed on the y-axis at each chromosomal position on the x-axis. The nearest gene to each genome-wide significant lead SNP is labeled at each locus, except when a cardiomyopathy-related gene is present within 250kb of the lead SNP.

Figure 2: PheWAS highlights the connection between a polygenic score for LVESVi and dilated cardiomyopathy

The polygenic score derived from LVESVi was applied to PheCodes (panel a) and curated disease phenotypes (panel b) in the UK Biobank. Each of the curated phenotypes is defined in **Supplemental Table 1**. For both panels (a) and (b), the X-axis represents the identifying code for the disease phenotype. The Y-axis represents the $-\log_{10}$ of the P-value of association between the polygenic score and the phenotype in a logistic model adjusted for age at enrollment, the genotyping array, sex, and the first five principal components of ancestry. Triangles oriented upward represent betas that are concordant with the LVESVi PRS (e.g., a

higher LVESVi PRS corresponds with a higher risk of DCM), and the reverse is true for downward-oriented triangles. The 3 most strongly associated phenotypes in each panel are labeled on the figure. The PheWAS plots for all seven cardiac MRI phenotypes are available in **Supplemental Figure 7**.

Figure 3: The LVESVi polygenic score influences risk for incident dilated cardiomyopathy

The cumulative DCM incidence over time is plotted for individuals in the bottom tenth percentile (blue), middle 80% (green) and top tenth percentile (red) for the LVESVi polygenic score. The 95% confidence intervals are represented with lighter colors. The X-axis represents the number of years since enrollment in the UK Biobank. The Y axis represents the cumulative incidence of DCM.